tetano
Editor, Senior Moderator
Med Microbiol Immunol
. 2022 Jan 16.
doi: 10.1007/s00430-021-00725-2. Online ahead of print.
Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality
Alexander Leatherdale[SUP] 1 2 [/SUP], Sophie Stukas[SUP] 3 4 [/SUP], Victor Lei[SUP] 1 2 [/SUP], Henry E West[SUP] 1 3 [/SUP], Christopher J Campbell[SUP] 5 [/SUP], Ryan L Hoiland[SUP] 6 7 [/SUP], Jennifer Cooper[SUP] 3 4 [/SUP], Cheryl L Wellington[SUP] 3 4 [/SUP], Mypinder S Sekhon[SUP] 8 [/SUP], Edward L G Pryzdial[SUP] #[/SUP][SUP] 1 3 9 [/SUP], Edward M Conway[SUP] #[/SUP][SUP] 10 11 12 [/SUP]
Affiliations
Abstract
Mechanisms underlying the SARS-CoV-2-triggered hyperacute thrombo-inflammatory response that causes multi-organ damage in coronavirus disease 2019 (COVID-19) are poorly understood. Several lines of evidence implicate overactivation of complement. To delineate the involvement of complement in COVID-19, we prospectively studied 25 ICU-hospitalized patients for up to 21 days. Complement biomarkers in patient sera and healthy controls were quantified by enzyme-linked immunosorbent assays. Correlations with respiratory function and mortality were analyzed. Activation of complement via the classical/lectin pathways was variably increased. Strikingly, all patients had increased activation of the alternative pathway (AP) with elevated levels of activation fragments, Ba and Bb. This was associated with a reduction of the AP negative regulator, factor (F) H. Correspondingly, terminal pathway biomarkers of complement activation, C5a and sC5b-9, were significantly elevated in all COVID-19 patient sera. C5a and AP constituents Ba and Bb, were significantly associated with hypoxemia. Ba and FD at the time of ICU admission were strong independent predictors of mortality in the following 30 days. Levels of all complement activation markers were sustained throughout the patients' ICU stays, contrasting with the varying serum levels of IL-6, C-reactive protein, and ferritin. Severely ill COVID-19 patients have increased and persistent activation of complement, mediated strongly via the AP. Complement activation biomarkers may be valuable measures of severity of lung disease and the risk of mortality. Large-scale studies will reveal the relevance of these findings to thrombo-inflammation in acute and post-acute COVID-19.
Keywords: Alternative pathway; COVID-19; Complement; Factor B; Hypoxemia; Innate immunity.
. 2022 Jan 16.
doi: 10.1007/s00430-021-00725-2. Online ahead of print.
Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality
Alexander Leatherdale[SUP] 1 2 [/SUP], Sophie Stukas[SUP] 3 4 [/SUP], Victor Lei[SUP] 1 2 [/SUP], Henry E West[SUP] 1 3 [/SUP], Christopher J Campbell[SUP] 5 [/SUP], Ryan L Hoiland[SUP] 6 7 [/SUP], Jennifer Cooper[SUP] 3 4 [/SUP], Cheryl L Wellington[SUP] 3 4 [/SUP], Mypinder S Sekhon[SUP] 8 [/SUP], Edward L G Pryzdial[SUP] #[/SUP][SUP] 1 3 9 [/SUP], Edward M Conway[SUP] #[/SUP][SUP] 10 11 12 [/SUP]
Affiliations
- PMID: 35034207
- DOI: 10.1007/s00430-021-00725-2
Abstract
Mechanisms underlying the SARS-CoV-2-triggered hyperacute thrombo-inflammatory response that causes multi-organ damage in coronavirus disease 2019 (COVID-19) are poorly understood. Several lines of evidence implicate overactivation of complement. To delineate the involvement of complement in COVID-19, we prospectively studied 25 ICU-hospitalized patients for up to 21 days. Complement biomarkers in patient sera and healthy controls were quantified by enzyme-linked immunosorbent assays. Correlations with respiratory function and mortality were analyzed. Activation of complement via the classical/lectin pathways was variably increased. Strikingly, all patients had increased activation of the alternative pathway (AP) with elevated levels of activation fragments, Ba and Bb. This was associated with a reduction of the AP negative regulator, factor (F) H. Correspondingly, terminal pathway biomarkers of complement activation, C5a and sC5b-9, were significantly elevated in all COVID-19 patient sera. C5a and AP constituents Ba and Bb, were significantly associated with hypoxemia. Ba and FD at the time of ICU admission were strong independent predictors of mortality in the following 30 days. Levels of all complement activation markers were sustained throughout the patients' ICU stays, contrasting with the varying serum levels of IL-6, C-reactive protein, and ferritin. Severely ill COVID-19 patients have increased and persistent activation of complement, mediated strongly via the AP. Complement activation biomarkers may be valuable measures of severity of lung disease and the risk of mortality. Large-scale studies will reveal the relevance of these findings to thrombo-inflammation in acute and post-acute COVID-19.
Keywords: Alternative pathway; COVID-19; Complement; Factor B; Hypoxemia; Innate immunity.